Microcrystalline Cellulose pH102: Your Essential Pharmaceutical Excipient
Discover the versatile benefits and applications of MCC pH102 for superior tablet and capsule formulations.
Get a Quote & SampleProduct Core Value
Microcrystalline Cellulose pH102
Microcrystalline Cellulose pH102 is a highly refined pharmaceutical excipient derived from purified cellulose. Its unique physicochemical properties make it invaluable in pharmaceutical tablet and capsule manufacturing, serving as a primary component for achieving desired drug delivery characteristics.
- Explore the microcrystalline cellulose tablet excipient properties for optimal formulation.
- Understand how MCC pH102 pharmaceutical grade contributes to tablet disintegration.
- Leverage its role as a high-performance direct compression filler binder.
- Learn about its application in complex pharmaceutical tablet formulation strategies.
Key Advantages
Exceptional Compressibility
Microcrystalline cellulose tablet excipient excels in compressibility, enabling the creation of robust tablets with consistent hardness and low friability.
Enhanced Disintegration
Its porous structure facilitates rapid water uptake, ensuring efficient tablet breakup and improved drug release as per tablet disintegration agent properties.
Versatile Functionality
Acting as a binder, filler, disintegrant, and lubricant, MCC pH102 streamlines formulations and reduces the need for multiple excipients in your pharmaceutical tablet formulation.
Key Applications
Tablet Manufacturing
As a leading direct compression filler binder, MCC pH102 is essential for producing high-quality tablets with excellent mechanical properties.
Capsule Formulation
Its inert nature and excellent flow make it an ideal diluent for capsule filling, ensuring uniform dosage delivery.
Wet Granulation Processes
MCC pH102 aids in the granulation process, improving granule properties and subsequent tablet performance.
Drug Release Optimization
Understanding tablet disintegration agent properties is key; MCC pH102 helps optimize drug release profiles for enhanced bioavailability.